OptiBiotix Health PLC Total Voting Rights (6403M)
01 August 2017 - 1:27AM
UK Regulatory
TIDMOPTI
RNS Number : 6403M
OptiBiotix Health PLC
31 July 2017
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Total Voting Rights
For the purposes of the Financial Conduct Authority's (FCA)
Disclosure and Transparency Rules, the issued ordinary share
capital of the Company comprises 78,543,318 ordinary shares of 2p
each ('Ordinary Shares').
The Company does not hold any Ordinary Shares in Treasury.
Therefore, the total number of Ordinary Shares carrying voting
rights in the Company is 78,543,318. Shareholders may use this
figure as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the Company, under the FCA's
Disclosure and Transparency Rules.
The Company has been made aware that as a result of a
typographical error on an application for admission in January 2015
sixty ordinary shares had not been admitted to trading on AIM.
Application has now been made for these sixty shares to be admitted
to trading on AIM which is expected to occur on or around 4 August
2017. There is no change to the issued share capital as a result of
this application, which was correctly notified at the time.
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via
Walbrook below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213
0880
Liam Murray / Jo Turner
finnCap (Broker) Tel: 020 7220
0500
Adrian Hargrave / Scott Mathieson
/ Kate Bannatyne (Corporate Finance)
Tony Quirke (Corporate Broking)
Walbrook PR Ltd Tel: 020 7933 8780 or optibiotix@walbrookpr.com
Anna Dunphy Mob: 07876 741
001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which
modify the human microbiome - the collective genome of the microbes
in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial
strains, compounds and formulations, which modulate the human
microbiome and can be used as food ingredients and supplements or
active compounds for the prevention and management of human
metabolic diseases, examples of which include obesity, cholesterol
and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators
that can impact on lipid and cholesterol management, energy harvest
and appetite suppression. The development pipeline is fuelled by
its proprietary OptiScreen(R) and OptiBiotic(R) platform
technologies designed to identify metabolic pathways and compounds
that impact on human physiology and bring potential health
benefits. These platforms are applicable across a wider range of
other human diseases.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRBUGDRLDXBGRB
(END) Dow Jones Newswires
July 31, 2017 11:27 ET (15:27 GMT)
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From Apr 2024 to May 2024
Optibiotix Health (LSE:OPTI)
Historical Stock Chart
From May 2023 to May 2024